Search clinical trials for: ASN100

Total 116 results

AffyImmune Therapeutics, Inc.

Recruiting

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Anaplastic Thyroid Cancer | Relapsed/Refractory Poorly Differentiated Thyroid Cancer

United States
Arsanis, Inc.

Terminated

Prevention of S. Aureus Pneumonia Study in Mechanically Ventilated Subjects Who Are Heavily Colonized With S. Aureus.

Pneumonia, Ventilator-associated | Pneumonia, Staphylococcal

United States, Spain, France, Czechia, Portugal, Israel, Romania, Russian Federation, Hungary, Poland, Ukraine, India, Austria, Georgia, Serbia, South Africa
Astellas Pharma Global Development, Inc.

Active, not recruiting

A Study of ASP1002 in Adults for Treatment of Solid Tumors

Advanced Solid Tumors

United States
TrialSpark

Completed

A Study to Evaluate the Anti-pruritic Effectiveness of ASN008 in Adults With Mild to Moderate Atopic Dermatitis

Dermatitis, Atopic | Pruritus

United States
Stanford University

Completed

Evaluating Safety and Efficacy of Herbal Treatment in Ulcerative Colitis (SA100)

Ulcerative Colitis

United States
Novartis Pharmaceuticals

Completed

Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

Healthy

United States
Asana BioSciences

Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Cancer | Lymphoma, Malignant | Myelofibrosis | Lymphoma, Mantle-Cell | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Tumor | Neoplasm | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | Idiopathic Myelofibrosis and other conditions

United States, Argentina
Novartis Pharmaceuticals

Withdrawn

Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. (MACS1881)

Chronic Myeloid Leukemia (CML)

Brazil
Dana-Farber Cancer Institute
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Completed

Nilotinib in TKI Resistant or Intolerant Patients With Metastatic Mucosal, Acral, or Chronically Sun Damaged Melanoma

Melanoma | Acral Melanoma | Mucosal Lentiginous Melanoma

United States
Abbott Nutrition

Not yet recruiting

Benefits of Nutritional Ingredients for Type 2 Diabetes

Diabetes type2
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
Capstone Therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of Additional Doses of AZX100 Drug Product Following Excision of Keloid Scars

Scar Prevention | Scar Reduction

United States
Novartis Pharmaceuticals

Completed

Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. (NILOdeepR)

Chronic Myeloid Leukemia

Germany
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Capstone Therapeutics

Completed

A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients

Scar Prevention | Scar Reduction

United States
Asana BioSciences

Completed

A Study of ASN007 in Patients With Advanced Solid Tumors

Cancer | Neoplasm Metastasis | Pancreatic Cancer | Metastatic Cancer | Metastatic Lung Cancer | Pancreas Adenocarcinoma | Metastatic Melanoma | Colon Cancer | Colonic Neoplasms | Pancreas Cancer | Non Small Cell Lung Cancer Metastatic | Neoplasm | Pancreas Neoplasm | Metastatic Pancreatic Cancer | Metastatic Colon Cancer and other conditions

United States
Gruppo Italiano Trapianto di Midollo Osseo

Completed

Phase I/II for Safety and Efficacy of Nilotinib in a Population Steroid-refractory/or Steroid-dependent cGVHD (Nilo-cGVHD)

Chronic Graft Versus Host Disease

Israel, Italy
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

Stem Cell Monitoring for CML Patients Undergoing Nilotinib Therapy

Chronic Myeloid Leukemia

United States
Novartis Pharmaceuticals

Completed

Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Chronic Myelogenous Leukemia

Turkey
Stanford University
Novartis

Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant Failure

United States, Canada
Rony Schaffel

Terminated

Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALLPhi)

Acute Lymphoblastic Leukemia | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
M.D. Anderson Cancer Center
Novartis

Withdrawn

Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Cancer
Asana BioSciences

Terminated

Study of ASN003 in Subjects With Advanced Solid Tumors

Melanoma | Neoplasms | Colorectal Neoplasm | Carcinoma, Non-small Cell Lung

United States
Capstone Therapeutics

Completed

A Study to Evaluate the Safety and Efficacy of AZX100 Drug Product Following Excision of Keloid Scars

Scar Prevention | Scar Reduction

United States
Asana BioSciences

Completed

Single Ascending Dose Study to Evaluate Pharmacokinetics and Food-Effect in Healthy Volunteers

Healthy Volunteers

United States
Novartis Pharmaceuticals

No longer available

Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

United States, Greece, Taiwan, Germany, Switzerland, United Kingdom, Russian Federation, Singapore, Ireland, Belgium, Italy, Spain, France, Netherlands, Korea, Republic of, Lebanon, Brazil, Canada, Turkey, China, Hungary, Denmark, A... and more
Royal Free Hospital NHS Foundation Trust
Acurable Ltd.

Recruiting

AcuPebble to Remotely Monitor Patients With OSA on CPAP Therapy

Sleep Apnea, Obstructive

United Kingdom
Ascletis Pharmaceuticals Co., Ltd.

Not yet recruiting

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

SARS CoV 2 Infection

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients (ENESTxtnd)

Chronic Myeloid Leukemia

Canada, Egypt, Saudi Arabia, Australia, Lebanon, South Africa, Israel, Russian Federation, Brazil, Thailand, Malaysia, Argentina, Taiwan, India, Oman, United Arab Emirates, Tunisia, Mexico, Algeria
Ascletis Pharmaceuticals Co., Ltd.

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

SARS CoV 2 Infection

China
Novartis Pharmaceuticals

Active, not recruiting

Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients (ENESTfreedom)

Chronic Myelogenous Leukemia

Belgium, Spain, Austria, Germany, Italy, France, Netherlands, Sweden, Japan, United States, Greece, United Kingdom, Bulgaria, Hungary, Argentina, Poland, Colombia, Ireland, Denmark
CellMed AG, a subsidiary of BTG plc.

Completed

Clinical Study to Investigate Safety and Tolerability and Pharmacokinetics of Multiple Ascending Doses of CM3.1-AC100 in Healthy Male Volunteers

Healthy

Germany
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy

Leukemia, Myeloid, Chronic

Israel
Kirilys Therapeutics Inc.

Active, not recruiting

Study of ASN004 in Patients With Advanced Solid Tumors (ASN004)

Solid Tumor

United States
Asana BioSciences

Terminated

Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
M.D. Anderson Cancer Center
Array BioPharma

Terminated

An Open-Label, Phase I/II Study of Nilotinib (Tasigna) and MEK-162 (ARRY-162) Used in Combination for Patients With Refractory or Advanced Chronic Myeloid Leukemia and Philadelphia Positive Acute Leukemia (Protocol CAMN107AUS41T)

Leukemia

United States
Asana BioSciences

Completed

Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)

Atopic Dermatitis

United States, Germany, Canada
Asana BioSciences

Completed

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

Dermatitis, Atopic | Dermatitis, Eczematous | Dermatitis Eczema

United States, Canada
Novartis Pharmaceuticals

Completed

Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor

Gastrointestinal Stromal Tumors (GIST)

Israel
Novartis Pharmaceuticals

Completed

Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Acute Lymphoblastic Leukemia (ALL) | Chronic Myelogenous Leukemia (CML) | Metastatic Gastrointestinal Stromal Tumors (GIST) | Receptor Tyrosine Kinase (KIT) Mutated Melanoma

Italy, United Kingdom, Canada, Singapore, Netherlands, France, Korea, Republic of, United States, Slovakia, Hungary, Russian Federation, Hong Kong, Spain, Israel, Sweden, Austria
Novartis Pharmaceuticals

Completed

Open Label, Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia (CML) Pediatric Patients. (DIALOG)

Philadelphia Positive (Ph+) Chronic Myelogenous Leukemia

United States, France, Korea, Republic of, Thailand, Italy, Netherlands, Turkey, Hungary, Russian Federation, Spain, United Kingdom, Japan, Malaysia
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)

Acute Lymphoblastic Leukemia | Chronic Myelogenous Leukemia

Japan
Kirilys Therapeutics, Inc.

Completed

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

Healthy Volunteer

United States
Novartis Pharmaceuticals

Completed

Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.

Gastrointestinal Stromal Tumors

Germany, Italy
Novartis Pharmaceuticals

Completed

Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response (MACS0911)

Philadelphia Chromosome Positive | Chronic Myelogenous Leukemia in Chronic Phase

Japan
Centagen, Inc.

Completed

Effects of a 10 Component Dietary Supplement on Health and the Quality of Life

Quality of Life | Stress | Blood Pressure | Joint Instability | Immune Deficiency | Lung Function Decreased | HDL Low | Energy Supply; Deficiency | Concentration Ability Impaired

United States
Novartis Pharmaceuticals

Completed

A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL)

Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia

Netherlands, Italy, France, United Kingdom
Novartis Pharmaceuticals

Completed

A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALL

Chronic Myelogenous Leukemia | Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)

Japan
Novartis Pharmaceuticals

Completed

Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase ('MACS1252)

CML in Chronic Phase

Germany, Italy, Spain, Belgium, Croatia, Hungary, Netherlands, Austria, France, Greece, Sweden, Switzerland, Bulgaria, Romania, Slovenia, United Kingdom, Lithuania, Slovakia, Denmark, Finland, Norway, Poland, Czech Republic, Portugal, E... and more
Novartis Pharmaceuticals

Completed

Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial

Chronic Myelogenous Leukemia

Poland

Search clinical trials for: ASN100

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations